

Title (en)
Detection and treatment of cancer

Title (de)
Detektion und Behandlung von Krebs

Title (fr)
Détection et traitement du cancer

Publication
EP 1955714 A1 20080813 (EN)

Application
EP 08002689 A 19950918

Priority
• US 30814194 A 19940919
• EP 95940906 A 19950918

Abstract (en)
A method for detecting cancer in a patient. The method comprises the steps of introducing labeled antibodies or labeled AFP to a biological sample of the patient so the labeled antibodies or labeled AFP will react with the AFP receptor binding sites in the biological sample. Next there is the step of identifying AFP receptor binding sites in the biological material which are reacted with the labeled antibodies or labeled AFP to determine the presence of cancer. Preferably, before the introducing step, there is the step of obtaining a biological sample from a body of a patient. A method for treating cancer cells in a patient. The method comprises the steps of introducing AFP receptor antibodies to cancer cells in the patient. Then there is the step of reacting the AFP receptor antibodies with the AFP receptor of the cancer cells to inhibit growth of the cancer cells or kill the cancer cells. A method for monitoring a patient. The method comprises the steps of treating the patient for cancer. Then there is the step of testing the patient at predetermined intervals after the treatment for AFP receptor site levels. A method for treating a patient. The method comprises the steps of testing the patient for AFP receptor. Then there is the step of introducing AFP receptor antibodies or AFP into the patient to react with cancer cells in the patient if the testing indicates AFP receptors are in the patient. A method for treating cancer cells in a patient. The method comprises the steps of introducing modified AFP to cancer cells in the patient. Then there is the step of reacting the modified AFP with the AFP receptor of the cancer cells to inhibit growth of the cancer cells or kill the cancer cells.

IPC 8 full level
A61K 38/16 (2006.01); **A61K 47/48** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 47/00** (2006.01); **A61P 35/00** (2006.01); **G01N 33/574** (2006.01); **G01N 33/68** (2006.01)

CPC (source: EP KR US)
A61K 47/50 (2017.08 - KR); **A61K 47/6817** (2017.08 - EP US); **A61K 47/6851** (2017.08 - EP US); **A61K 51/1045** (2013.01 - EP US); **A61P 35/00** (2018.01 - EP); **C07K 16/30** (2013.01 - EP US); **G01N 33/574** (2013.01 - KR); **G01N 33/57476** (2013.01 - EP US); **G01N 33/577** (2013.01 - KR); **A61K 2039/505** (2013.01 - EP US); **Y10S 977/92** (2013.01 - EP US)

Citation (applicant)
• ABELEV, G.I. ET AL., TRANSPLANTATION, vol. 1, 1963, pages 174
• RUOSLAHTI, E.; SEPPALS, M., INT. J. CANCER, vol. 8, 1971, pages 374
• RUOSLAHTI, E.; SEPPALS, M., ADV. CANCER RES., vol. 29, 1979, pages 275
• BENNO, R.H.; WILLIAMS, T.H., BRAIN RES., vol. 142, 1978, pages 1982
• TROJAN, J.; URIEL, J., J. ONCODEVELOP. BIOL. MED., vol. 1, 1980, pages 107
• URIEL, J. ET AL., PATH. BIOL., vol. 30, 1982, pages 79
• MORO, R.; URIEL, J., J. ONCODEVELOP. BIOL. MED., vol. 2, 1981, pages 391
• DZIEGIELEWSKA, K.M. ET AL., J. PHYSIOL., vol. 318, 1981, pages 239
• MOLLGARD, K. ET AL., NEUROSCI. LETT., vol. 14, 1979, pages 85
• URIEL, J. ET AL., ANN. N.Y. ACAD. SCI., vol. 417, 1983, pages 321
• TORAND-ALLERAND, C.D., NATURE, vol. 286, 1980, pages 733
• FIELTIZ, W.; ESTEVES, A.; MORO, R., DEV. BRAIN RES., vol. 13, 1984, pages 111
• ALI, M.; RAUL, H.; SAHIB, M., DEV. BRAIN RES., vol. 1, 1981, pages 618
• ALI, M.; MUJOO, K.; SAHIB, M., DEV. BRAIN RES., vol. 6, 1983, pages 47
• SCHACHTER, B.S.; TORAN-ALLERAND, C.D., DEV. BRAIN RES., vol. 5, 1982, pages 95
• PIEIRO, A. ET AL., INT. J. BIOCHEM., vol. 14, 1982, pages 817
• URIEL, J. ET AL., NEUROSCI. LETT., vol. 27, 1981, pages 171
• HAJERI-GERMOND, M.; TROJAN, URIEL, J.; HAUW, J.J., DEV. NEUROSCI., vol. 6, 1984, pages 111
• VILLACAMPA, M.J. ET AL., DEV. BRAIN RES., vol. 12, 1984, pages 77
• MORO, R. ET AL., INT. J. DEV. NEUROSCI., vol. 2, 1984, pages 143
• TROJAN, J.; URIEL, J., ONCODEV. BIOL. MED., vol. 3, 1982, pages 13
• FIELTIZ, W.; ESTEVES, A.; MORO, R., DEV. BRAIN RES., vol. 13, 1984
• MORO, R., NEUROSCI. LETT., vol. 41, 1983, pages 253
• JACOBSEN, M.; LASSEN, L.C.; MOLLGARD, K., TUMOR BIOL., vol. 5, 1984, pages 55
• URIEL, J. ET AL., PROC. NAT. ACAD. SCI. U.S.A., vol. 73, 1976, pages 1452
• SMALLEY, J.R.; SARCIONE, E.J., BIOCH. BIOHYS. RES. COMM., vol. 94, 1980, pages 429
• SARCIONE, E.J.; HART, D., INT. J. CANCER, vol. 35, 1985, pages 315
• URIEL, J. ET AL., TUMOR BIOL., vol. 5, 1984, pages 41
• URIEL, J.; POUPON, M.F.; GEUSKENS, M., BR. J. CANCER, vol. 48, 1983, pages 263
• VILLACAMPA, M.J. ET AL., BIOCH. BIOPHYS. RES. COMMUN., vol. 122, 1984, pages 1322
• NAVAL, J. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 3301
• URIEL, J. ET AL., C.R. ACAD. SCI., vol. 297, 1983, pages 589
• URIEL, J. ET AL., CANCER RES., vol. 44, 1984, pages 5314
• MORO, R. ET AL., NUCLEAR MED. COMM., vol. 5, 1984, pages 5
• HAJERI-GERMOND, M. ET AL., BR. J. CANCER, vol. 51, 1985, pages 791
• NAVAL, J. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 3301
• BIDDLE, W.; SARCIONE, E.J., BREAST CANCER RES. TREAT., vol. 10, 1987, pages 281
• LABORDA, J. ET AL., INT. J. CANCER, vol. 40, 1987, pages 314
• CALVO, M. ET AL., XIII MEETING OF THE ISOBM, 1985
• TORRES, J.M.; ANEL, A.; URIEL, J., J. CELL PHYSIOL., vol. 150, 1992, pages 458

- TORRES, J.M.; GUESKENS, M.; URIEL, J., INT. J. CANCER, vol. 47, 1991, pages 112
- TORRES, J.M. ET AL., MOL. IMMUNOLOGY, vol. 26, 1989, pages 851
- SUZUKI, Y.; ZENG, C.Q.; ALPERT, E.J., CLINIC. INVEST., vol. 90, 1992, pages 1530
- ESTEBAN, C.; GUESKENS, M.; URIEL, J., INT. J. CANCER, vol. 49, 1991, pages 425
- MORO, R. ET AL., TUMOUR BIOL., vol. 14, 1993, pages 116

Citation (search report)

- [X] WO 9419021 A1 19940901 - INTROMED LTD [VG], et al
- [X] R. MORO ET AL.: "Monoclonal antibodies against a widespread oncofetal antigen: the alpha-fetoprotein receptor.", TUMOR IMMUNOLOGY, vol. 14, no. 2, 1 July 1993 (1993-07-01), BASEL CH, pages 116 - 130, XP000561002

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

Designated extension state (EPC)

LT LV SI

DOCDB simple family (publication)

WO 9609551 A1 19960328; AT E449342 T1 20091215; AU 3764895 A 19960409; AU 714966 B2 20000113; BR 9508959 A 19971230; CA 2197490 A1 19960328; CN 100472213 C 20090325; CN 1132012 C 20031224; CN 1169778 A 19980107; CN 1502994 A 20040609; DE 69536019 D1 20091231; DK 0782709 T3 20100329; EP 0782709 A1 19970709; EP 0782709 B1 20091118; EP 1955714 A1 20080813; EP 1956374 A1 20080813; ES 2336976 T3 20100419; FI 121353 B 20101015; FI 970990 A0 19970310; FI 970990 A 19970310; KR 970706498 A 19971103; NO 323754 B1 20070702; NO 971256 D0 19970318; NO 971256 L 19970318; RU 2161042 C2 20001227; US 6514685 B1 20030204

DOCDB simple family (application)

IB 9500902 W 19950918; AT 95940906 T 19950918; AU 3764895 A 19950918; BR 9508959 A 19950918; CA 2197490 A 19950918; CN 200310104769 A 19950918; CN 95195125 A 19950918; DE 69536019 T 19950918; DK 95940906 T 19950918; EP 08002689 A 19950918; EP 08002690 A 19950918; EP 95940906 A 19950918; ES 95940906 T 19950918; FI 970990 A 19970310; KR 19970701775 A 19970319; NO 971256 A 19970318; RU 97106059 A 19950918; US 92065497 A 19970815